➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: May 12, 2021

DrugPatentWatch Database Preview

Details for Patent: 6,821,987

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,821,987 protect, and when does it expire?

Patent 6,821,987 protects FOTIVDA and is included in one NDA.

Summary for Patent: 6,821,987
Title: Quinoline derivatives and quinazoline derivatives having azolyl group
Abstract:An object of the present invention is to provide compounds having potent antitumor activity. The compounds according to the present invention are compounds represented by formula (I) or pharmaceutically acceptable salts or solvates thereof: ##STR1## wherein X and Z represent CH or N; Y represents O or S; R.sup.1, R.sup.2, and R.sup.3 represent H, alkoxy or the like; R.sup.4 represents H; R.sup.5, R.sup.6, R.sup.7, and R.sup.8 represent H, halogen, alkoxy or the like; R.sup.9 and R.sup.10 represent H, alkyl or the like; and R.sup.11 represents optionally substituted azolyl.
Inventor(s): Kubo; Kazuo (Takasaki, JP), Sakai; Teruyuki (Takasaki, JP), Nagao; Rika (Takasaki, JP), Fujiwara; Yasunari (Saitama, JP), Isoe; Toshiyuki (Takasaki, JP), Hasegawa; Kazumasa (Takasaki, JP)
Assignee: Kirin Beer Kabushiki Kaisha (Tokyo-to, JP)
Application Number:10/132,473
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 6,821,987

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Aveo Pharms FOTIVDA tivozanib hydrochloride CAPSULE;ORAL 212904-001 Mar 10, 2021 RX Yes No   Get Started for $10   Get Started for $10 Y Y   Get Started for $10
Aveo Pharms FOTIVDA tivozanib hydrochloride CAPSULE;ORAL 212904-002 Mar 10, 2021 RX Yes Yes   Get Started for $10   Get Started for $10 Y Y   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,821,987

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2001-132775Apr 27, 2001

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.